Details of the Drug
General Information of Drug (ID: DM10AUP)
Drug Name |
Biphenyl-3-ylcarbamic acid cyclohexyl ester
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
565460-15-3; URB602; cyclohexyl biphenyl-3-ylcarbamate; Cyclohexyl [1,1'-biphenyl]-3-ylcarbamate; URB-602; UNII-B8371SFA9K; CHEMBL77767; Monoacylglycerol Lipase Inhibitor, URB602; biphenyl-3-ylcarbamic acid cyclohexyl ester; B8371SFA9K; URB 602; N-Biphenyl-3-ylcarbamic acid, cyclohexyl ester; N-[1,1'-Biphenyl]-3-yl-carbamic Acid Cyclohexyl Ester; SCHEMBL4274165; Cyclohexylbiphenyl-3-ylcarbamate; CTK8C4433; DTXSID90450611; HHVUFQYJOSFTEH-UHFFFAOYSA-N; MolPort-003-850-812; EX-A1228; BCP19101; BDBM50128581; ANW-71925; ZINC13520725
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 295.4 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 4.9 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 4 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||